Abstract:In chronic eosinophilic leukemia, the transforming oncoprotein FIP1L1-PDGFRA is a major target of therapy. In most patients, the tyrosine kinase inhibitor (TKI) imatinib induces complete remission. For patients who are intolerant or resistant, novel TKIs have been proposed. We examined the in vitro effects of 14 kinase blockers on growth and function of EOL-1 cells, a FIP1L1-PDGFRA(+) eosinophil cell line. Major growth-inhibitory effects were seen with all PDGFR-blocking agents, with IC50 values in the low nanomolar range: ponatinib, 0.1-0.2 nmol/L; sorafenib, 0.1-0.2 nmol/L; masitinib, 0.2-0.5 nmol/L; nilotinib, 0.2-1.0 nmol/L; dasatinib, 0.5-2.0 nmol/L; sunitinib, 1-2 nmol/L; midostaurin, 5-10 nmol/L. These drugs were also found to block activation of PDGFR-downstream signaling molecules, including Akt, S6, and STAT5 in EOL-1 cells. All effective TKIs produced apoptosis in EOL-1 cells as determined by microscopy, Annexin-V/PI, and caspase-3 staining. In addition, PDGFR-targeting TKIs were found to inhibit cytokine-induced migration of EOL-1 cells. In all bioassays used, ponatinib was found to be the most potent compound in EOL-1 cells. In addition, ponatinib was found to downregulate expression of the activation-linked surface antigen CD63 on EOL-1 cells and to suppress the growth of primary neoplastic eosinophils. We also examined drug effects on Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V. Strong inhibitory effects on both mutants were seen only with ponatinib. In summary, novel PDGFR-targeting TKIs may be alternative agents for the treatment of patients with imatinib-resistant chronic eosinophilic leukemia. Although several different PDGFR-targeting agents are effective, the most potent drug appears to be ponatinib.

Research Progress of Multi-targeted Tyrosine Kinase Inhibitor-Ponatinib

Ponatinib: An update on its drug targets, therapeutic potential and safety

Ponatinib‐review of historical development, current status, and future research

Multi-targeted Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: an Era of Individualized Therapy.

The Research Progress of New Targeted Therapy Drugs Lpatinib

[Current Status and Future Direction of Multi-Targeted Drugs in the Era of Personalized Therapy--overview of Advances in Multi-Targeted Therapy in Non-Small Cell Lung Cancer].

A Potent Small Molecule Compound Might Overcome High Level Drug Resistant Mutations of Bcr-Abl1

Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development

Research Progress in Quinazoline Derivatives As Multi-Target Tyrosine Kinase Inhibitors

Discovery of Novel Ponatinib Analogues for Reducing Kdr Activity As Potent Fgfrs Inhibitors

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Comparative Efficacy and Safety of Different Doses of Ponatinib Versus Other Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia: a Systematic Review and Network Meta-Analysis.

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Sunitinib: a novel multitargeted receptor tyrosine kinase inhibitor

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

How Does the Novel T315L Mutation of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Confer Resistance to Ponatinib: a Comparative Molecular Dynamics Simulation Study

Current Status of Research and Development of New Tyrosine Kinase Inhibitors

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors As Anticancer Agents